Phase I Dose Escalation Study of Carboplatin, Pemetrexed and Exemestane in Post-menopausal Women With Metastatic Non-squamous NSCLC
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2017
At a glance
- Drugs Carboplatin (Primary) ; Exemestane (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker
- 12 Sep 2017 Planned End Date changed from 1 Aug 2015 to 30 Sep 2019.
- 12 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 30 Sep 2018.
- 07 Sep 2016 Status changed from recruiting to active, no longer recruiting.